| Document |
Document Title |
|
WO/2007/139128 |
Disclosed is a composition for inhibiting the secretion of creatine phosphokinase (CPK). The composition comprises a peptide mixture prepared by enzymatically degrading 11S soybean protein as an active ingredient.
|
|
WO/2007/138994 |
Disclosed is a compound represented by the general formula (1) or a pharmaceutically acceptable salt thereof: (1) Also disclosed is a pharmaceutical composition comprising the compound.
|
|
WO/2007/134867 |
The present invention refers to compounds of the general formulae Ia to Ie as defined above for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and i...
|
|
WO/2007/134867 |
The present invention refers to compounds of the general formulae Ia to Ie as defined above for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and i...
|
|
WO/2007/132841 |
Disclosed is a serotonin 5-HT2C receptor activator comprising a compound represented by the formula below or a salt or prodrug thereof: (I) wherein the ring A represents a 5- or 6-membered aromatic heterocyclic ring which may have a subs...
|
|
WO/2007/132888 |
[PROBLEMS] To provide a smooth muscle contraction inhibitor that can be stably supplied, inhibiting the smooth muscle contraction not dependent upon calcium ion without influencing the normal smooth muscle contraction dependent upon calc...
|
|
WO/2007/128465 |
The present invention refers to compounds of the general formulae I as defined above, preferably α-mangostin, for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for t...
|
|
WO/2007/129473 |
The object is to provide a novel compound which has an S1P receptor agonist activity, can fully act as an immunosuppressant, has few adverse side-effects, and can be administered through the oral route. Disclosed is an S1P receptor agoni...
|
|
WO/2007/130031 |
The use of therapeutics capable of inhibiting complement such as an anti-C5 antibody to treat muscular dystrophy associated with dysferlin-deficiency is disclosed.
|
|
WO/2007/125246 |
The invention concerns the use of a compound of formula (I) such as defined in Claim 1, for preparing a medicine for treating or preventing conditions corresponding to muscular degeneration of skeletal muscles, such as muscular myopathie...
|
|
WO/2007/125245 |
The invention concerns the use of a compound inducing an increase of free serotonin rate in the body, for preparing a medicine for treating conditions corresponding to muscular degeneration of skeletal muscles such as muscular myopathies...
|
|
WO/2007/122976 |
Disclosed is a therapeutic agent for polyglutamine disease or an inhibitor of the development of polyglutamine disease, which comprises, as an active ingredient, the following component (1) or (2): (1) (i) an HGF protein or (ii) a peptid...
|
|
WO/2007/122721 |
[PROBLEMS] To provide a fiber and fiber products such as a mat, clothes and a vest which are therapeutically usable anywhere, show no side effect and can easily relieve the symptoms of fibromuscular pain. [MEANS FOR SOLVING PROBLEMS] A f...
|
|
WO/2007/119833 |
It is intended to provide a compound which has an ACC inhibitory effect, is useful in preventing and treating obesity, diabetes, hypertension and so on and has excellent characteristics in drug effect, duration of the action, specificity...
|
|
WO/2007/117022 |
Disclosed is a chewing composition which can elute coenzyme Q10 contained in the composition into an oral cavity with high elution rate. Also disclosed is a method for improving the elution of coenzyme Q10 into an oral cavity, specifical...
|
|
WO/2007/115776 |
The invention relates to the use of a compound of the formula (I) or a pharmaceutically acceptable addition salt thereof for the preparation of a medicament for the prophylaxis and/or treatment of muscular dystrophies or myopathies resul...
|
|
WO/2007/116962 |
Studies are made on the effects of the inhibition of the IL-6 signal pathway on the growth of muscular cells. As a result, it is found out that the administration of an IL-6 inhibitor can promote the adhesion, proliferation and different...
|
|
WO/2007/113540 |
Methods, compositions and substances for regulating fat and carbohydrate oxidation in the muscle tissue of human and/or animal bodies, which involve controlling the carnitine content of the muscle tissue. Regulating carbohydrate and fat ...
|
|
WO/2007/114213 |
[PROBLEMS] To provide a compound capable of inhibiting the production of a prostaglandin or leukotriene. [MEANS FOR SOLVING PROBLEMS] Disclosed is a compound represented by the general formula (I) or a salt thereof: (I) wherein (a) repre...
|
|
WO/2007/113540 |
Methods, compositions and substances for regulating fat and carbohydrate oxidation in the muscle tissue of human and/or animal bodies, which involve controlling the carnitine content of the muscle tissue. Regulating carbohydrate and fat ...
|
|
WO/2007/113540 |
Methods, compositions and substances for regulating fat and carbohydrate oxidation in the muscle tissue of human and/or animal bodies, which involve controlling the carnitine content of the muscle tissue. Regulating carbohydrate and fat ...
|
|
WO/2007/110977 |
It is intended to develop a method for fundamentally healing a disease by improving the cognitive ability of the brain. It was found that the cognitive ability of the brain is improved and, consequently, treatment of a given disease incl...
|
|
WO/2007/108434 |
It is intended to provide a means which is efficacious in digesting a protein forming aggregates in a eukaryotic cell such as mutant superoxide dismutase 1 or an androgen receptor having an abnormally extended polyglutamine chain. Namely...
|
|
WO/2007/108530 |
A muscle fatigue remedy that for persons with the symptoms of muscle pain attributed to strenuous exercise, lassitude in the arms and legs attributed to quick exercise, low back pain and stiffness in the shoulder attributed to taking of ...
|
|
WO/2007/106884 |
Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment for a muscular wasting disease, an NF-KB activation inhib...
|
|
WO/2007/104780 |
The invention relates to the R-enantiomer of N-carbamoylmethyl-4-phenyl-2-pyrrolidinone (R- Carphedon) of pharmacological value. The method of its preparation includes the N-alkylation of 4(R)-phenyl-2-pyrrolidinone with ethyl bromoaceta...
|
|
WO/2007/104780 |
The invention relates to the R-enantiomer of N-carbamoylmethyl-4-phenyl-2-pyrrolidinone (R- Carphedon) of pharmacological value. The method of its preparation includes the N-alkylation of 4(R)-phenyl-2-pyrrolidinone with ethyl bromoaceta...
|
|
WO/2007/101937 |
The present invention relates to a composition containing at least one amidine derivative or carboxamide derivative of general formula (I) or (A) in combination with at least one compound chosen from steroids, corticoids or corticosteroi...
|
|
WO/2007/102515 |
An extensive study is made on a compound having a PPAR-activating activity. As a result, it is found that a 2-phenylthiazole derivative having a carboxymethyl sulfanylphenyl group or an equivalent thereof has a PPARγ-activating activity...
|
|
WO/2007/100695 |
The present invention relates to metabolic regulators that affect metabolic function, for example metabolic regulators that affect muscle mass, muscle regeneration, muscle hypertrophy, fat mass, insulin and glucose sensitivity, angiogene...
|
|
WO/2007/100695 |
The present invention relates to metabolic regulators that affect metabolic function, for example metabolic regulators that affect muscle mass, muscle regeneration, muscle hypertrophy, fat mass, insulin and glucose sensitivity, angiogene...
|
|
WO/2007/099151 |
The present invention relates to novel methods for enhancing endogenous protection mechanisms against oxidative stress, and agents for use in such methods. In particular, the present invention provides a pharmaceutical composition which ...
|
|
WO/2007/100695 |
The present invention relates to metabolic regulators that affect metabolic function, for example metabolic regulators that affect muscle mass, muscle regeneration, muscle hypertrophy, fat mass, insulin and glucose sensitivity, angiogene...
|
|
WO/2007/097289 |
Disclosed is an organ-selective androgen receptor modulator comprising a compound represented by the formula (I') or a salt thereof or a prodrug of the compound or the salt: (I') wherein the ring A represents a 5- to 8-membered ring whic...
|
|
WO/2007/098106 |
Methods for treating systemic or local diseases or conditions by administering an interferon as therapeutic agent to one or several regions of the respiratory tract are provided. In one embodiment, the interferon is interferon-tau.
|
|
WO/2007/098106 |
Methods for treating systemic or local diseases or conditions by administering an interferon as therapeutic agent to one or several regions of the respiratory tract are provided. In one embodiment, the interferon is interferon-tau.
|
|
WO/2007/097205 |
It is intended to provide eyedrops which have an ocular tension-lowering effect and a hypotensive effect based on novel function mechanisms. The above-described eyedrops contain a muscle-relaxing agent as the active ingredient and dantro...
|
|
WO/2007/094404 |
An optically active carboxylic acid compound can be produced by hydrolyzing an optically active acylated camphorsultam with an aqueous solution of an alkali earth metal hydroxide in the presence of a branched alkanol, whereby a correspon...
|
|
WO/2007/093183 |
The present invention relates to the use of gaboxadol, or a combination of gaboxadol and one or more anti-inflammatory compounds, for the treatment of an inflammatory disease. The present invention further relates to a pharmaceutical com...
|
|
WO/2007/093183 |
The present invention relates to the use of gaboxadol, or a combination of gaboxadol and one or more anti-inflammatory compounds, for the treatment of an inflammatory disease. The present invention further relates to a pharmaceutical com...
|
|
WO/2007/091107 |
There are disclosed compound of Formula (I) or (II) wherein A1, A2, A3, A4and A5, which may be the same or different, represent N or CR1, R9 represents - L -R3, in which L is a single bond or a linker group and R3 represents hydrogen or ...
|
|
WO/2007/091396 |
Disclosed is a compound having S1P receptor antagonist activity, which is useful as an immunosuppressive agent. The compound has few side effects, and is orally administrable. Specifically disclosed are a compound represented by the gene...
|
|
WO/2007/091106 |
There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4,...
|
|
WO/2007/088050 |
The invention relates to a method of treatment for muscular dystrophies, including Duchenne, Becker, limb-girdle, facioscapulohumeral, congenital muscular dystrophies and the like using a combination of nitric oxide-releasing and anti-in...
|
|
WO/2007/088123 |
The present invention relates to the use of nitric oxide releasing compounds for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.
|
|
WO/2007/088050 |
The invention relates to a method of treatment for muscular dystrophies, including Duchenne, Becker, limb-girdle, facioscapulohumeral, congenital muscular dystrophies and the like using a combination of nitric oxide-releasing and anti-in...
|
|
WO/2007/088895 |
Disclosed is a pharmaceutical composition which is intended to be administered to a patient who needs the inhibition of 11β-HSD1 or the control of 11β-HSD1 activity. The pharmaceutical composition comprises a 3-arylamino-1,2,4-triazole...
|
|
WO/2007/088123 |
The present invention relates to the use of nitric oxide releasing compounds for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.
|
|
WO/2007/085728 |
The invention concerns a composition comprising at least: one botulic neurotoxin type A1, and one botulic neurotoxin type A the amino acid sequence of which has at least 5% difference with the amino acid sequence of the botulic neurotoxi...
|
|
WO/2007/086565 |
Disclosed is a growth hormone secretion regulator or anti-aging agent comprising aspartic acid and valine as active ingredients. Also disclosed is a pharmaceutical, food, nutritional supplement or feeding stuff comprising the growth horm...
|
